Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Alkermes Plc (NASDAQ:ALKS)

54.57
Delayed Data
As of Feb 17
 -0.98 / -1.76%
Today’s Change
27.14
Today|||52-Week Range
60.74
-1.82%
Year-to-Date
Alkermes (ALKS) Q4 Loss Narrower than Expectations, Sales Beat
Feb 16 / Zacks.com - Paid Partner Content
PRIMECAP Management Buys AstraZeneca PLC, Alkermes PLC, Whirlpool, Sells Union Pacifi...
Feb 13 / GuruFocus News - Paid Partner Content
Why Sage Therapeutics Jumped Today
Feb 13 / MotleyFool.com - Paid Partner Content
Is Alkermes Poised for a Comeback in 2017?
Feb 06 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close55.55
Today’s open55.03
Day’s range54.01 - 55.64
Volume860,925
Average volume (3 months)1,088,740
Market cap$8.3B
Dividend yield--
Data as of 3:59pm ET, 02/17/2017

Growth & Valuation

Earnings growth (last year)+9.21%
Earnings growth (this year)--
Earnings growth (next 5 years)+57.70%
Revenue growth (last year)+18.68%
P/E ratioNM
Price/Sales11.29
Price/Book6.88

Competitors

 Today’s
change
Today’s
% change
JAZZJazz Pharmaceuticals...+0.78+0.57%
RDYDr.Reddy's Laborator...-0.12-0.28%
SGENSeattle Genetics Inc+0.20+0.31%
UTHRUnited Therapeutics ...-0.26-0.15%
Data as of 4:02pm ET, 02/17/2017

Financials

Last reporting dateFebruary 15, 2017
EPS forecast (this quarter)$0.05
Annual revenue (last year)$745.7M
Annual profit (last year)-$208.4M
Net profit margin-27.95%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman &
Chief Executive Officer
Richard F. Pops
President
Shane M. Cooke
Corporate headquarters
Dublin, Dublin

Forecasts


Search for Jobs